Homocystinuria is a group of rare inherited metabolic disorders in which the body cannot properly process the amino acid homocysteine, allowing it to build up in the blood and urine. The most common form, often called “classical” homocystinuria, results from a deficiency of the enzyme cystathionine beta-synthase (CBS), which normally helps convert homocysteine into another amino acid called cystathionine.1PubMed Central. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency Though individually rare, the condition touches nearly every organ system and carries risks that range from dislocated eye lenses in childhood to blood clots in young adults. The story of homocystinuria is also one of underdiagnosis, with evidence suggesting that far more people carry the genetic variants than ever receive a clinical diagnosis.
What Causes Homocystinuria
Classical homocystinuria is inherited as an autosomal recessive trait, meaning a child must receive a faulty copy of the CBS gene from each parent to develop the condition.2PubMed Central. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment When CBS does not work, the normal pathway that converts the sulfur-containing amino acid methionine through homocysteine and then into cysteine gets blocked at the homocysteine step. The result is a buildup of homocysteine and a shortage of cysteine and its downstream products.
But CBS deficiency is not the only route to homocystinuria. A separate group of disorders, called remethylation defects, impair the recycling of homocysteine back into methionine. These involve enzymes like methylenetetrahydrofolate reductase (MTHFR) and methionine synthase, and they cause homocysteine to accumulate through a different bottleneck.3PubMed Central. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency From a laboratory standpoint, both types share elevated homocysteine, but they differ in methionine levels: classical homocystinuria tends to raise methionine, while remethylation defects tend to lower it.4PubMed. Laboratory evaluation of homocysteine remethylation disorders and classic homocystinuria: Long-term follow-up using a cohort of 123 patients That distinction matters because the treatments differ and because newborn screening programs that look only at methionine will miss remethylation defects entirely.
How Homocystinuria Affects the Body
Excess homocysteine is toxic to connective tissue, blood vessels, and the nervous system. The clinical picture of classical homocystinuria typically unfolds across four organ systems: the eyes, the skeleton, the vascular system, and the brain. Not every patient develops problems in all four areas, and severity varies enormously depending on how much residual enzyme activity a person retains and how early treatment begins.
Eyes
Dislocation of the lens of the eye, called ectopia lentis, is one of the earliest and most recognizable signs. In one classic comparison study, dislocated lenses were found in close to 90% of eyes in patients with homocystinuria.5American Journal of Ophthalmology. Ocular manifestations in the Marfan syndrome and homocystinuria The lens in homocystinuria tends to shift downward, and in roughly a third of cases it dislocates completely into the vitreous cavity or the front chamber of the eye. This often shows up in early childhood and may be the finding that first leads doctors to investigate further. Severe myopia is also common, and some patients develop glaucoma as a secondary complication of the displaced lens.
Skeleton
Patients with classical homocystinuria tend to be tall and thin, with long limbs and long fingers, which is part of the reason the condition gets confused with Marfan syndrome. But the bone changes have their own signature. Skeletal studies of patients with CBS deficiency emphasize excessive bone growth that produces structurally weaker bone than normal. The most characteristic findings include disproportionately long lower limbs relative to the trunk, abnormally shaped vertebrae, chest wall deformities like pectus excavatum, knock knees, and widened ends of the long bones.6PubMed Central. Skeletal abnormalities in homocystinuria Osteoporosis at an unusually young age is another hallmark, with vertebral compression fractures sometimes occurring in teenagers.
Blood Clots
Vascular complications are the most dangerous feature of untreated homocystinuria. Elevated homocysteine damages the inner lining of blood vessels through several mechanisms, including reducing the availability of nitric oxide (which normally keeps vessels relaxed and blood flowing smoothly), increasing oxidative stress, and promoting inflammation.7PubMed Central. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide The clinical result is a dramatically elevated risk of both arterial and venous blood clots, starting at a young age.8Cor et Vasa. Homocysteine and venous thromboembolism—Is there any link? Some reports indicate that more than half of untreated patients will experience at least one clot before the age of 30.9Advances in Clinical and Medical Research. Homocystinuria Presenting as a Simultaneous Dual-Site Venous Thrombosis
There is an interesting interaction with other clotting risk factors. In one study of 11 patients with homocystinuria, all six who developed blood clots also carried factor V Leiden, a separate and much more common inherited clotting tendency. The four patients with homocystinuria who did not carry factor V Leiden remained clot-free.10PubMed. Coexistence of hereditary homocystinuria and factor V Leiden–effect on thrombosis This suggests that homocystinuria alone may not always be enough to trigger clotting in every patient, and that co-existing risk factors can amplify the danger considerably.
Brain and Mental Health
Intellectual disability occurs in a significant fraction of patients who are diagnosed late or go untreated. Less well known are the psychiatric features. A study examining 25 patients with homocystinuria found that roughly two-thirds had clinically meaningful psychological or psychiatric symptoms, with anxiety and depression each reported in about a third of the group.11Genetics in Medicine. Revising the Psychiatric Phenotype of Homocystinuria Mood swings, aggression, suicidal thoughts, and obsessive-compulsive symptoms have also been described.12PubMed Central. Obsessive-Compulsive Symptoms as a Manifestation of Homocystinuria These psychiatric features are probably underrecognized because the metabolic condition itself is rare, and the psychiatric symptoms look indistinguishable from ordinary anxiety or depression unless someone thinks to check homocysteine levels.
Why It Gets Confused with Marfan Syndrome
On the surface, homocystinuria and Marfan syndrome look remarkably alike. Both produce tall, slender individuals with long limbs, long fingers, dislocated lenses, scoliosis, and chest wall deformities. A case report described a woman who carried a suspected Marfan diagnosis from age 12 until age 26, when genetic testing for Marfan-related genes came back negative and further investigation revealed homocystinuria instead.13Molecular Genetics and Metabolism Reports. Think classical homocystinuria if the genetic test did not confirm Marfan syndrome: Late diagnosis and phenotypic variability in adult siblings with classical homocystinuria
Several clinical clues help separate the two. Osteoporosis and blood clots are features of homocystinuria but not Marfan syndrome. Intellectual disability and skin flushing point toward homocystinuria. Conversely, dramatic scoliosis and very pronounced long fingers tend to be more florid in Marfan syndrome, and the lens dislocation tends to be upward in Marfan versus downward in homocystinuria.14JAMA. Homocystinuria: Studies of 20 Families With 38 Affected Members The widened ends of long bones visible on X-rays are a distinctive skeletal feature of homocystinuria that Marfan patients do not share.15The Journal of Bone and Joint Surgery. British volume. HOMOCYSTINURIA AND MARFAN’S SYNDROME Still, the overlap is substantial enough that biochemical testing is necessary to make the final call. Any young patient with a Marfan-like body type and unexplained blood clots, early osteoporosis, or intellectual disability should have their homocysteine measured.
How Homocystinuria Is Diagnosed
Many countries include homocystinuria in their newborn screening programs, but the standard approach has an important limitation. Screening typically uses tandem mass spectrometry to measure methionine in a dried blood spot. This catches classical homocystinuria, in which methionine is elevated, but it generates false positives and misses remethylation defects entirely because those conditions lower methionine rather than raising it.16PubMed Central. Newborn Screening for Homocystinuria Revealed a High Frequency of MAT I/III Deficiency in Iberian Peninsula One major source of false positives is methionine adenosyltransferase deficiency, a generally benign condition that also raises methionine. Adding a direct measurement of homocysteine as a second-tier test substantially improves accuracy. Newer methods that incorporate homocysteine measurement into the first-tier screening assay are under development and show promise for reducing false positives while catching true cases more reliably.17Clinical Chemistry. Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization
When homocystinuria is suspected outside the newborn period, the first step is measuring total plasma homocysteine. Values in classical homocystinuria are typically extremely high. Confirmation can come from direct measurement of CBS enzyme activity in plasma or from genetic testing to identify mutations in the CBS gene. A plasma-based CBS activity assay has been developed that clearly separates most CBS-deficient patients from controls, though one particular mutation (D444N) actually elevates measured CBS activity in plasma, which could be confusing if the assay were used alone without genetic context.18PubMed. Enzymatic diagnosis of homocystinuria by determination of cystathionine-ß-synthase activity in plasma using LC-MS/MS Genetic testing is valuable not just for diagnosis but also for predicting whether a patient will respond to vitamin B6 therapy, which depends heavily on which mutations they carry.
Treatment Approaches
The first thing clinicians assess after a diagnosis of classical homocystinuria is whether the patient is “pyridoxine responsive,” meaning their residual CBS enzyme works better with high doses of vitamin B6 (pyridoxine). Pyridoxine-responsive patients tend to have milder disease and can sometimes achieve good homocysteine control with vitamin supplementation alone or in combination with a moderately restricted diet. Pyridoxine-nonresponsive patients face a tougher road: they typically need a strictly methionine-restricted diet starting from infancy, along with additional therapies to push homocysteine levels down.
Betaine is a key medication for patients who do not respond adequately to pyridoxine. It works by providing a methyl group that allows homocysteine to be converted back into methionine through an alternative pathway, bypassing the broken CBS step. In a study of 10 patients with pyridoxine-nonresponsive CBS deficiency, adding betaine to their existing treatment produced a substantial decrease in homocysteine levels, and six of the ten showed immediate clinical improvement with no adverse effects.19PubMed. Homocystinuria–the effects of betaine in the treatment of patients not responsive to pyridoxine Betaine therapy has also been shown to help prevent the vascular events that cause the most serious harm in homocystinuria.20PubMed. The use of betaine in the treatment of elevated homocysteine
Even with the current toolkit of dietary restriction, pyridoxine, betaine, and supplemental folate and B12, many patients struggle to keep homocysteine levels consistently within a safe range.21PubMed. Homocystinuria: Therapeutic approach The methionine-restricted diet is demanding. Methionine is found in all protein, so patients must limit natural protein intake severely and supplement with a special methionine-free amino acid formula. For children, compliance is manageable with parental oversight, but adolescents and young adults often drift off their diets. The consequences of poor control are cumulative: every year of elevated homocysteine adds to the risk of lens dislocation, blood clots, and bone loss.
Why Early Detection Changes Outcomes
The evidence for catching homocystinuria through newborn screening and starting treatment early is compelling. An Irish program that screened newborns and treated patients with dietary restriction from infancy reviewed 18 screened and treated cases and found no homocystinuria-related complications across a combined total of over 365 patient-years of follow-up, compared with the historically grim rates of complications in untreated patients.22PubMed. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years’ experience of a newborn screened and treated population with reference to clinical outcome and biochemical control A Japanese long-term follow-up confirmed similar findings: nearly all patients detected by newborn screening had normal intellectual development and were working or attending school, though some still developed complications over time, underscoring that screening buys a head start but does not eliminate all risk.23PubMed Central. Long-Term Outcomes of Adult Patients with Homocystinuria before and after Newborn Screening
The contrast with late diagnosis is stark. Patients who are not identified until they develop symptoms, sometimes not until their twenties or thirties, have often already sustained lens dislocations, skeletal deformity, or blood clots. Treatment can slow further damage and reduce future risk, but it cannot reverse what has already occurred. The woman misdiagnosed with Marfan syndrome for 14 years is a sobering example of how delayed recognition plays out in practice.
Pregnancy and Homocystinuria
Women with homocystinuria can and do have successful pregnancies, but the combination of pregnancy’s natural tendency toward clotting and homocystinuria’s vascular toxicity requires careful management. An Irish review of pregnancy outcomes in women with CBS deficiency highlighted the importance of tight metabolic control and noted predictable risks including pre-eclampsia and superficial vein clots.24PubMed Central. The challenges of pregnancy management in pyridoxine nonresponsive homocystinuria: The Irish experience A broader analysis of reproductive outcomes in women with homocystinuria found that pregnancy complications and birth defects were infrequent, suggesting that the outlook is usually normal, but recommended monitoring metabolic therapy closely and considering anticoagulation during pregnancy and the postpartum period.25PubMed. Reproductive fitness in maternal homocystinuria due to cystathionine beta-synthase deficiency The methionine-restricted diet adds a logistical layer, since pregnancy increases protein needs and the amino acid formula must be adjusted carefully to support fetal growth without raising homocysteine.
Emerging Enzyme-Replacement Therapy
For patients who cannot achieve adequate control with existing treatments, a new class of therapy is in development. Pegtibatinase is an engineered enzyme designed to break down homocysteine directly in the bloodstream. In a phase 1/2 clinical trial, patients receiving the treatment saw their average total homocysteine levels drop from about 97 micromoles per liter at baseline to about 32 micromoles per liter, a reduction of roughly two-thirds. Two of four participants in the treatment group reached levels below 50, and one reached the normal range below 15.26Elsevier / GIM Open. Safety and Efficacy of Pegtibatinase in Classical Homocystinuria: Results from the Phase 1/2 COMPOSE Study These are early-stage results in a small group, but the magnitude of the reduction is striking given that many patients on conventional therapy struggle to keep their levels below 100. If larger trials confirm these findings, enzyme replacement could transform management for pyridoxine-nonresponsive patients who currently rely on restrictive diets they find difficult to follow.
The Hidden Iceberg of Undiagnosed Cases
One of the more provocative findings in recent years is that the number of people walking around with two copies of certain CBS mutations is far larger than the number of diagnosed homocystinuria patients. A re-examination of population genetics data in Denmark found that the expected number of individuals homozygous for the widespread I278T mutation, based on how common the carrier state is, vastly exceeds the number who have ever been clinically identified. The researchers concluded that most of these individuals may be clinically unaffected, or may not develop problems until the third decade of life or later, presenting with blood clots rather than the full-blown childhood picture of lens dislocation and skeletal abnormalities.27PubMed Central. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency
This matters for two reasons. First, the classic descriptions of homocystinuria may reflect a biased sample of the most severely affected patients, the ones sick enough to come to medical attention as children. The milder end of the spectrum, people with partial enzyme activity who develop subtler or later problems, may be going unrecognized. Second, it raises the question of whether population-wide newborn screening, while excellent at catching the severe cases, is also inadvertently missing milder forms that would still benefit from monitoring or early treatment. There is no consensus on what to do about this gap yet, but it is a reminder that rare diseases are sometimes only rare because of how we look for them.
The MTHFR Polymorphism Confusion
A common source of public confusion involves the MTHFR gene. Two widespread polymorphisms in MTHFR, particularly the well-known C677T variant, mildly reduce the enzyme’s activity. People who are homozygous for the C677T variant (meaning they inherited the variant from both parents) have moderately reduced MTHFR function, which can lead to modestly elevated homocysteine levels, especially if their folate intake is low.28PubMed. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences This is emphatically not the same as homocystinuria. Severe MTHFR deficiency, caused by rare mutations that virtually eliminate enzyme activity, does cause a form of homocystinuria with serious neurological and vascular consequences.29PubMed Central. Homocystinuria: Advances in metabolic and molecular therapies targeting homocysteine pathways But the common polymorphisms are just that: common. Roughly 10 to 15 percent of many populations are homozygous for C677T. The modest elevation in homocysteine they cause typically falls in the range of 40 to 100 micromoles per liter only when combined with poor folate status, and it is correctable with adequate folate intake.30Journal of Clinical Pathology. Homocystinuria diagnosis and management: it is not all classical The online wellness industry has generated enormous anxiety about these polymorphisms, but they should not be conflated with the serious inborn errors that cause clinical homocystinuria.